assignment and transfer of Arizona fourth-priority Colorado River water in the amount of 762 acre-feet per year from CVIDD to be divided amongst the Beneficiaries. Amend CVIDD's Colorado River water delivery contract No. 2–07–30–W0028 to decrease its Colorado River water entitlement from 8,204.52 to 7,442.52 acre-feet per year. Enter into Colorado River water delivery contracts for Arizona fourth-priority Colorado River water entitlements under contract No. 21–XX–30–W0717 with The Cibola Sportsman's Club, Inc. for 216 acre-feet per year, contract No. 21–XX–30–W0718 with Alfred F. and Erma Jean Bishop Family Trust for 420 acre-feet per year, and contract No. 21–XX–30–W0719 with Bruce and Lora Cathcart and James and Maria Cathcart for 126 acre-feet per year.

21. City of Needles, BCP, California: Approve a new point of diversion under contract No. 05–XX–30–W0445, as amended, dated March 16, 2007, and contract No. 2–07–30–W0280, as amended, dated July 3, 2002, and revise the necessary exhibits of the above-referenced contracts to add an additional point of diversion.

Columbia-Pacific Northwest—Interior Region 9: Bureau of Reclamation, 1150 North Curtis Road, Suite 100, Boise, Idaho 83706–1234, telephone 208–378–5344.

The Columbia-Pacific Northwest—Interior Region 9 has no updates to report for this quarter.

California-Great Basin—Interior Region 10: Bureau of Reclamation, 2800 Cottage Way, Sacramento, California 95825–1898, telephone 916–978–5250.

Discontinued contract action:

3. Contractors from the Delta Division, Cross Valley Canal, and West San Joaquin Division; CVP; California: Renewal of 10 interim and long-term water service contracts; water quantities for these contracts total in excess of 148,000 acre-feet. These contract actions will be accomplished through long-term renewal contracts pursuant to Public Law 102–575. Prior to completion of negotiation of long-term renewal contracts, existing interim renewal water service contracts may be renewed through successive interim renewal of contracts.

Completed contract actions:

40. Tehama-Colusa Canal Authority, CVP, California: Renewal of OM&R contract. Contract completed on September 28, 2021.

42. Shasta County Water Agency, CVP, California: Proposed partial assignment of 50 acre-feet of the Shasta County Water Agency's CVP water supply to the City of Shasta Lake for M&I use. Contract completed on August 9, 2021.

43. Friant Water Authority, CVP, California: Negotiation and execution of a repayment contract for Friant Kern Canal Middle Reach Capacity Correction Project. Contract completed on September 23, 2021.

Christopher Beardsley,

Director, Policy and Programs.

[FR Doc. 2021–24762 Filed 11–12–21; 8:45 am]

BILLING CODE 4332–90–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–688F]

Final Adjusted Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ephedrine, Pseudoephedrine, and Phenylpropanolamine for 2021

AGENCY: Drug Enforcement Administration, Department of Justice.

ACTION: Final order.

SUMMARY: This final order establishes the final adjusted 2021 aggregate production quotas for controlled substances in schedules I and II of the Controlled Substances Act and the assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine.

DATES: This order is effective November 15, 2021.

FOR FURTHER INFORMATION CONTACT: Scott A. Brinks, Regulatory Drafting and Policy Support Section, Diversion Control Division, Drug Enforcement Administration; Mailing Address: 8701 Morrissette Drive, Springfield, VA 22152, Telephone: (571) 362–3261.

SUPPLEMENTARY INFORMATION:

Legal Authority

Section 306 of the Controlled Substances Act (CSA) (21 U.S.C. 826) requires the Attorney General to establish aggregate production quotas (APQ) for each basic class of controlled substances listed in schedules I and II and for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine. The Attorney General has delegated this function to the Administrator of the Drug Enforcement Administration (DEA) pursuant to 28 CFR 0.100.

Background

DEA published the 2021 established APQ for controlled substances in schedules I and II and for the assessment of annual needs (AAN) for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine in the **Federal Register** on November 30, 2020. 85 FR 76604. DEA is committed to preventing and limiting diversion by enforcing laws and regulations regarding controlled substances and the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, while meeting the legitimate medical, scientific, and export needs of the United States. This notice stated that the Administrator would adjust, as needed, the established APQ in 2021 in accordance with 21 CFR 1303.13 and 21 CFR 1315.13.

The 2021 proposed adjusted APQ for controlled substances in schedules I and II and AAN for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine were subsequently published in the **Federal Register** on September 2, 2021, (86 FR 49346), after consideration of the criteria outlined in that notice. All interested persons were invited to comment on or object to the proposed APQs and AANs on or before October 4, 2021.

Comments Received

DEA received 27 timely comments in response to the September **Federal Register** notice from patients, DEA-registered entities, and non-DEA entities. The comments included appreciation of DEA's response to the increased interest in research using hallucinogenic controlled substances, requests to increase the APQ for additional hallucinogenic controlled substances, requests to increase the APQ for select schedule II controlled substances, concerns regarding the inability to comment to the notice electronically for two weeks, and comments outside the scope of this final order.

Issue: Commenters expressed appreciation of DEA's flexibility in responding to the nationwide public interest in hallucinogenic controlled substances research.

DEA Response: DEA acknowledges the expressions of appreciation to changes in the APQ for these controlled substances. The adjustments to select hallucinogenic schedule I controlled substances occurred after DEA received additional schedule I researcher protocols from DEA registered researchers and quota applications from DEA registered manufacturers.

Issue: Commenters requested DEA to increase the APQ for Bufotenine, Dimethyltryptamine (DMT), N,N-Dimethyltryptamine, 5-Methoxy-N,N-

dimethyltryptamine (5MEODMT), Ibogaine, Ketamine, Lysergic Acid Diethylamide (LSD), 3,4-Methylenedioxymethamphetamine (MDMA), Mescaline, Mitragynine, and Psilocybin in response to the nationwide public interest in hallucinogenic controlled substances research.

DEA Response: Ketamine is a schedule III controlled substance and therefore is outside of the scope of this final order as DEA only sets APQs for substances controlled in schedules I and II. DEA received additional quota applications for DMT, MDMA, and Psilocybin and considered the timely provided information in those applications for this final order. Regarding the other controlled substances listed, DEA has not received quota applications from DEA-registered manufacturers to support the requested changes in the APQ for these controlled substances. Mitragynine is not a controlled substance and therefore is outside the scope of this final order.

Issue: DEA-registered entities requested that the APQ for Methadone, Methadone Intermediate, Methylphenidate Oxycodone (for sale), Phenylacetone, and Thebaine be sufficient to provide for the estimated medical, scientific, research, and industrial needs of the United States, for export requirements, and for the establishment and maintenance of reserve stocks.

DEA Response: DEA sets APQ in a manner to ensure that the estimated medical, scientific, research, industrial needs of the United States, lawful export requirements, and for the establishment and maintenance of reserve stocks. As discussed in the notice for adjustment, any adjustments to the APQ for a controlled substance are based on factors set forth in 21 CFR 1303.13. In the event of a shortage, the CSA provides a mechanism under which DEA will, in appropriate circumstances, increase quotas to address shortages. 21 U.S.C. 826(h). Under 21 U.S.C. 826(h)(1), after receiving a request to address a shortage, DEA has 30 days to complete review of the request and determine whether adjustments are necessary to address the shortage. If adjustments are necessary, DEA is required to increase the APQ and individual production quotas to alleviate the shortage. *Id.* If DEA determines adjustments are not necessary, DEA is required to ''provide a written response detailing the basis for the . . . determination.'' *Id.* In addition to what Section 826(h)(1) requires, when DEA is notified of an alleged shortage, DEA will confer with the Food and Drug Administration and relevant manufacturers regarding the amount of material in physical inventory, current quota granted, and the estimated legitimate medical need, to determine whether a quota adjustment is necessary to alleviate any quota-related drug shortage.

In accordance with 21 CFR 1303.13, DEA considered the comments for Bufotenine, 5-Methoxy-N,N-dimethyltryptamine (5MEODMT), Ibogaine, Lysergic Acid Diethylamide (LSD), Mescaline, Methadone, Methadone Intermediate, Oxycodone (for sale), and Thebaine and the Administrator determined the proposed adjusted 2021 APQs for these substances as published in the **Federal Register** on September 2, 2021, (86 FR 49346), are sufficient to meet the current 2021 estimated medical, scientific, research, and industrial needs of the United States, lawful export requirements, and to provide for adequate reserve stock.

Issue: Commenters expressed general concerns regarding the inability to submit electronic comments to the notice published on September 2, 2021, for two weeks. Commenters requested an extension of the comment period to allow for additional comments.

DEA Response: DEA acknowledges that commenters could not submit electronic comments to the notice for two weeks. However, written comments could be submitted via mail to the address provided in the notice. Written comments that were postmarked on or before October 4, 2021, were considered in this final order. DEA notes that one commenter submitted identical electronic and written comments both of which were timely postmarked, received, and considered for this final order.

Out of Scope Comments: DEA received comments on issues outside the scope of this final order. Commenters made several suggestions to the DEA, including: (1) Seeking assistance from indigenous communities to determine the amount of psychedelic substances that would be needed to conduct research; (2) making the United States a signatory to the *Nagoya Protocol and the Convention on Biological Diversity;* and (3) creating diversified categories for production and research on psilocybin-containing fungi fruiting bodies/sclerotia/liquid culture similar to cannabis (flower), fruiting body extract (akin to cannabis extract), and psilocybin and psilocin separately as purified compounds (akin to delta-9-thc). Regarding this last suggestion, the commenter further suggested that the ''same system should then be replicated in regards to lophophora/mescaline, as well as other plants, fungi and lifeforms, which produce these compounds being used in whole or closer to whole ways.''

DEA received other comments that were general in nature and raised issues of specific medical illnesses and medical treatments. All of the issues raised are outside of the scope of this final order for 2021 and do not impact the original analysis involved in finalizing the 2021 APQ.

Analysis for Final Adjusted 2021 Aggregate Production Quotas and Assessment of Annual Needs

In determining the final adjusted 2021 APQ and AAN, DEA considered the above comments relevant to this final order for calendar year 2021, along with the factors set forth in 21 CFR 1303.13 and 21 CFR 1315.13, in accordance with 21 U.S.C. 826(a). DEA has also considered other relevant factors, including the 2020 year-end inventories, initial 2021 manufacturing and import quotas, 2021 export requirements, actual and projected 2021 sales, research and product development requirements, additional applications received, and the extent of any diversion of the controlled substance in the class. Based on all of the above, the Administrator is adjusting the 2021 APQ for the following: 3,4-Methylenedioxymethamphetamine (MDMA), 4,4′-Dimethylaminorex, Dimethyltryptamine (DMT), Lisdexamfetamine, Methiopropamine, Psilocybin, Psilocyn, and Phenylacetone. This final order reflects those adjustments.

Pursuant to the above, the Administrator hereby finalizes the 2021 APQ for the following schedule I and II controlled substances and the 2021 AAN for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine, expressed in grams of anhydrous acid or base, as follows:

Basic class	Final adjusted 2021 quotas (g)
Schedule I	
1-[1-(2-Thienyl)cyclohexyl]pyrrolidine	20
1-(1-Phenylcyclohexyl)pyrrolidine	30
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine	10
1-(5-Fluoropentyl)-3-(1-naphthoyl)indole (AM2201)	30
1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole (AM694)	30
1-Benzylpiperazine	25
1-Methyl-4-phenyl-4-propionoxypiperidine	10
1-[1-(2-Thienyl)cyclohexyl]piperidine	15
2'-fluoro 2-fluorofentanyl	30
2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C–E)	30
2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C–D)	30
2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C–N)	30
2-(2,5-Dimethoxy-4-n-propylphenyl)ethanamine (2C–P)	30
2-(2,5-Dimethoxyphenyl)ethanamine (2C–H)	100
2-(4-Bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25B–NBOMe; 2C–B–NBOMe; 25B; Cimbi-36)	30
2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C–C)	30
2-(4-Chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25C–NBOMe; 2C–C–NBOMe; 25C; Cimbi-82)	25
2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C–I)	30
2-(4-Iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine (25I–NBOMe; 2C–I–NBOMe; 25I; Cimbi-5)	30
2,5-Dimethoxy-4-ethylamphetamine (DOET)	25
2,5-Dimethoxy-4-n-propylthiophenethylamine	25
2,5-Dimethoxyamphetamine (DMA)	25
2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C–T–2)	30
2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C–T–4)	30
3,4,5-Trimethoxyamphetamine	30
3,4-Methylenedioxyamphetamine (MDA)	55
3,4-Methylenedioxymethamphetamine (MDMA)	3,200
3,4-Methylenedioxy-N-ethylamphetamine (MDEA)	40
3,4-Methylenedioxy-N-methylcathinone (methylone)	40
3,4-Methylenedioxypyrovalerone (MDPV)	35
3–FMC; 3-Fluoro-N-methylcathinone	25
3-Methylfentanyl	30
3-Methylthiofentanyl	30
4′-Methyl acetyl fentanyl	30
4,4'-Dimethylaminorex	30
4-Bromo-2,5-dimethoxyamphetamine (DOB)	30
4-Bromo-2,5-dimethoxyphenethylamine (2–CB)	25
4-Chloro-α-pyrrolidinovalerophenone (4-chloro-alpha-PVP)	25
4CN-Cumyl-Butanica, 1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboximide	25
4F–MDMB–BINACA	30
4-Fluoroisobutyryl fentanyl	30
4–FMC; Flephedrone	25
4–MEC; 4-Methyl-N-ethylcathinone	25
4-Methoxyamphetamine	150
4-Methyl-2,5-dimethoxyamphetamine (DOM)	25
4-Methylaminorex	25
4-Methyl-N-methylcathinone (mephedrone)	45
4-Methyl-α-ethylaminopentiophenone (4–MEAP)	25
4-Methyl-α-pyrrolidinohexiophenone (MPHP)	25
4-Methyl-α-pyrrolidinopropiophenone (4-MePPP)	25
5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol	50
5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol or CP–47,497 C8-homolog)	40
5F–CUMYL–PINACA	25
5F–EDMB–PINACA	25
5F–MDMB–PICA	25
5F–AB–PINACA; N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide	25
5F–CUMYL–P7AICA; (1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboximide)	25
5F–ADB; 5F–MDMB–PINACA (methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate)	30
5F–AMB (methyl 2-(1-(5-fluoropentyl)-1*H*-indazole-3-carboxamido)-3-methylbutanoate)	30
5F–APINACA; 5F–AKB48 (*N*-(adamantan-1-yl)-1-(5-fluoropentyl)-1*H*-indazole-3-carboxamide)	30
5-Fluoro-PB–22; 5F–PB–22	20
5-Fluoro-UR144, XLR11 ([1-(5-fluoro-pentyl)-1*H*-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone	25
5-Methoxy-3,4-methylenedioxyamphetamine	25
5-Methoxy-N,N-diisopropyltryptamine	25
5-Methoxy-N,N-dimethyltryptamine	35
AB–CHMINACA	30
AB–FUBINACA	50

Basic class	Final adjusted 2021 quotas (g)
AB–PINACA	30
ADB–FUBINACA (*N*-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1*H*-indazole-3-carboxamide)	30
Acetorphine	25
Acetyl Fentanyl	100
Acetyl-*alpha*-methylfentanyl	30
Acetyldihydrocodeine	30
Acetylmethadol	25
Acryl Fentanyl	25
ADB–PINACA (*N*-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1*H*-indazole-3-carboxamide)	50
AH–7921	30
All other tetrahydrocannabinol	1,000
Allylprodine	25
Alphacetylmethadol	25
alpha-Ethyltryptamine	25
Alphameprodine	25
Alphamethadol	25
Alphaprodine	25
alpha-Methylfentanyl	30
alpha-Methylthiofentanyl	30
alpha-Methyltryptamine (AMT)	25
alpha-Pyrrolidinobutiophenone (α-PBP)	25
alpha-Pyrrolidinoheptaphenone (PV8)	25
alpha-Pyrrolidinohexanophenone (α-PHP)	25
alpha-Pyrrolidinopentiophenone (α-PVP)	25
Aminorex	25
Anileridine	20
APINCA, AKB48 (*N*-(1-adamantyl)-1-pentyl-1*H*-indazole-3-carboxamide)	25
Benzethidine	25
Benzylmorphine	30
Betacetylmethadol	25
beta-Hydroxy-3-methylfentanyl	30
beta-Hydroxyfentanyl	30
beta-Hydroxythiofentanyl	30
beta-Methyl fentanyl	30
beta-Phenyl fentanyl	30
Betameprodine	25
Betamethadol	4
Betaprodine	25
Brorphine	30
Bufotenine	15
Butylone	25
Butyryl fentanyl	30
Cathinone	40
Clonitazene	25
Codeine methylbromide	30
Codeine-N-oxide	192
Cyclopentyl Fentanyl	30
Cyclopropyl Fentanyl	20
Cyprenorphine	25
d-9–THC	384,460
Desomorphine	25
Dextromoramide	25
Diapromide	20
Diethylthiambutene	20
Diethyltryptamine	25
Difenoxin	9,200
Dihydromorphine	753,500
Dimenoxadol	25
Dimepheptanol	25
Dimethylthiambutene	20
Dimethyltryptamine	3,200
Dioxyaphetyl butyrate	25
Dipipanone	25
Drotebanol	25
Ethylmethylthiambutene	25
Etorphine	30
Etoxeridine	25
Fenethylline	30
Fentanyl carbamate	30
Fentanyl related substances	600

Basic class	Final adjusted 2021 quotas (g)
FUB–144	25
FUB–AKB48	25
FUB–AMB, MMB-Fubinaca, AMB-Fubinaca	25
Furanyl fentanyl	30
Furethidine	25
gamma-Hydroxybutyric acid	29,417,000
Heroin	45
Hydromorphinol	40
Hydroxypethidine	25
Ibogaine	30
Isobutyryl Fentanyl	25
JWH–018 and AM678 (1-Pentyl-3-(1-naphthoyl)indole)	35
JWH–019 (1-Hexyl-3-(1-naphthoyl)indole)	45
JWH–073 (1-Butyl-3-(1-naphthoyl)indole)	45
JWH–081 (1-Pentyl-3-[1-(4-methoxynaphthoyl)]indole)	30
JWH–122 (1-Pentyl-3-(4-methyl-1-naphthoyl)indole)	30
JWH–200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole)	35
JWH–203 (1-Pentyl-3-(2-chlorophenylacetyl)indole)	30
JWH–250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole)	30
JWH–398 (1-Pentyl-3-(4-chloro-1-naphthoyl)indole)	30
Ketobemidone	30
Levomoramide	25
Levophenacylmorphan	25
Lysergic acid diethylamide (LSD)	40
MAB–CHMINACA; ADB–CHMINACA (*N*-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1*H*-indazole-3-carboxamide)	30
MDMB–CHMICA; MMB–CHMINACA(methyl 2-(1-(cyclohexylmethyl)-1*H*-indole-3-carboxamido)-3,3-dimethylbutanoate)	30
MDMB–FUBINACA (methyl 2-(1-(4-fluorobenzyl)-1*H*-indazole-3-carboxamido)-3,3-dimethylbutanoate)	30
MMB–CHMICA-(AMB–CHMICA); Methyl-2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-methylbutanoate	25
Marihuana	2,000,000
Marihuana extract	500,000
Mecloqualone	30
Mescaline	25
Methaqualone	60
Methcathinone	25
Methiopropamine	30
Methyoxyacetyl fentanyl	30
Methyldesorphine	5
Methyldihydromorphine	25
Morpheridine	25
Morphine methylbromide	5
Morphine methylsulfonate	5
Morphine-N-oxide	150
MT–45	30
Myrophine	25
NM2201; Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate	25
N,N-Dimethylamphetamine	25
Naphyrone	25
N-Ethyl-1-phenylcyclohexylamine	25
N-Ethyl-3-piperidyl benzilate	10
N-Ethylamphetamine	24
N-Ethylhexedrone	25
N-Ethylpentylone, ephylone	30
N-Hydroxy-3,4-methylenedioxyamphetamine	24
N-Methyl-3-Piperidyl Benzilate	30
Nicocodeine	25
Nicomorphine	25
Noracymethadol	25
Norlevorphanol	2,550
Normethadone	25
Normorphine	40
Norpipanone	25
Ocfentanil	25
Ortho-fluorofentanyl, 2-fluorofentanyl	30
ortho-Fluoroacryl fentanyl	30
ortho-Fluorobutyryl fentanyl	30
ortho-Fluoroisobutyryl fentanyl	30
ortho-Methyl acetylfentanyl	30
ortho-Methyl methoxyacetyl fentanyl	30
Para-chloroisobutyryl fentanyl	30

Basic class	Final adjusted 2021 quotas (g)
Para-fluorofentanyl	25
Para-fluorobutyryl fentanyl	25
para-Fluoro furanyl fentanyl	30
para-Methylfentanyl	30
Para-methoxybutyryl fentanyl	30
Parahexyl	5
PB–22; QUPIC	20
Pentedrone	25
Pentylone	25
Phenadoxone	25
Phenampromide	25
Phenomorphan	25
Phenoperidine	25
Phenyl fentanyl	30
Pholcodine	5
Piritramide	25
Proheptazine	25
Properidine	25
Propiram	25
Psilocybin	6,000
Psilocyn	3,500
Racemoramide	25
SR–18 and RCS–8 (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole)	45
SR–19 and RCS–4 (1-Pentyl-3-[(4-methoxy)-benzoyl]indole)	30
Tetrahydrofuranyl fentanyl	15
Thebacon	25
Thiafentanil	25
Thiofentanyl	25
Thiofuranyl fentanyl	30
THJ–2201 ([1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone)	30
Tilidine	25
Trimeperidine	25
UR–144 (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone	25
U–47700	30
Valeryl fentanyl	25
Schedule II	
1-Phenylcyclohexylamine	15
1-Piperidinocyclohexanecarbonitrile	25
4-Anilino-N-phenethyl-4-piperidine (ANPP)	937,758
Alfentanil	3,260
Alphaprodine	25
Amobarbital	20,100
Bezitramide	25
Carfentanil	20
Cocaine	68,576
Codeine (for conversion)	1,612,500
Codeine (for sale)	27,616,684
D-amphetamine (for sale)	21,200,000
D,l-amphetamine	21,200,000
D-amphetamine (for conversion)	16,068,789
Dextropropoxyphene	35
Dihydrocodeine	156,713
Dihydroetorphine	25
Diphenoxylate (for conversion)	14,100
Diphenoxylate (for sale)	770,800
Ecgonine	68,576
Ethylmorphine	30
Etorphine hydrochloride	32
Fentanyl	731,452
Glutethimide	25
Hydrocodone (for conversion)	1,250
Hydrocodone (for sale)	30,821,224
Hydromorphone	2,743,101
Isomethadone	30
L-amphetamine	30
Levo-alphacetylmethadol (LAAM)	25
Levomethorphan	30
Levorphanol	26,495
Lisdexamfetamine	22,500,000

Basic class	Final adjusted 2021 quotas (g)
L-methamphetamine	587,229
Meperidine	856,695
Meperidine Intermediate-A	30
Meperidine Intermediate-B	30
Meperidine Intermediate-C	30
Metazocine	15
Methadone (for sale)	25,619,700
Methadone Intermediate	27,673,600
Methamphetamine	50
D-methamphetamine (for conversion)	485,020
D-methamphetamine (for sale)	40,000
Methylphenidate (for conversion)	15,300,000
Methylphenidate (for sale)	57,438,334
Metopon	25
Moramide-intermediate	25
Morphine (for conversion)	3,376,696
Morphine (for sale)	26,505,995
Nabilone	62,000
Norfentanyl	25
Noroxymorphone (for conversion)	22,044,741
Noroxymorphone (for sale)	376,000
Oliceridine	22,500
Opium (powder)	250,000
Opium (tincture)	530,837
Oripavine	33,010,750
Oxycodone (for conversion)	620,887
Oxycodone (for sale)	57,110,032
Oxymorphone (for conversion)	28,204,371
Oxymorphone (for sale)	563,174
Pentobarbital	30,766,670
Phenazocine	25
Phencyclidine	35
Phenmetrazine	25
Phenylacetone	6,100,000
Piminodine	25
Racemethorphan	5
Racemorphan	5
Remifentanil	3,000
Secobarbital	172,100
Sufentanil	4,000
Tapentadol	13,447,541
Thebaine	57,137,944
List I Chemicals	
Ephedrine (for conversion)	100
Ephedrine (for sale)	4,136,000
Phenylpropanolamine (for conversion)	14,878,320
Phenylpropanolamine (for sale)	16,690,000
Pseudoephedrine (for conversion)	1,000
Pseudoephedrine (for sale)	174,246,000

The Administrator further proposes that APQ for all other schedule I and II controlled substances included in 21 CFR 1308.11 and 1308.12 remain at zero.

Anne Milgram,

Administrator.

[FR Doc. 2021–24921 Filed 11–10–21; 4:15 pm]

BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

[OMB Number 1117–0034]

Agency Information Collection Activities; Proposed eCollection, eComments Requested; Revision of a Currently Approved Collection; The National Forensic Laboratory Information System Collection of Analysis Data

AGENCY: Drug Enforcement Administration, Department of Justice.

ACTION: 30-Day Notice.

SUMMARY: The Department of Justice (DOJ), Drug Enforcement Administration (DEA), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995. This proposed information collection was previously published in the **Federal Register** at 86 FR 47523 on August 25, 2021, allowing for a 60 day comment period. No comments were received.